Rallybio Corporation
RLYB
FAIR PRICE VALUATION
Updated daily
Model: DCF 50% · Relative 30% · Consensus 20%
MARKET PRICE
$9.11
FAIR PRICE
$7.28
MARGIN
$1.83
P/E Ratio
N/A
Div. Yield
N/A
ROE
-25.2%
Market Cap
$48M
Small-cap
COMING SOON
Get notified when RLYB's fair price changes
Fair Price Index app is launching soon with push notifications when valuations shift for stocks you follow.
iOS and Android · Free tier available
KEY FACTS
CEO
Martin W. MacKay
COUNTRY
US
HEADQUARTERS
New Haven
SECTOR
Healthcare
EXCHANGE
NASDAQ
METHODOLOGY
How we calculate RLYB's fair price
Rallybio Corporation's fair price of $7.28 is derived from a blended model that combines DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%). At the current market price of $9.11, RLYB trades 20.1% above its calculated fair value.
DCF MODEL · 50%
Discounted cash flow analysis based on projected free cash flows, discounted at a rate reflecting RLYB's risk profile.
RELATIVE · 30%
Comparing RLYB's valuation multiples against Healthcare peers.
ANALYST · 20%
Aggregated analyst price targets for RLYB, weighted by recency and analyst accuracy.
POWERED BY BULIOS
Get full analysis, financials, and AI insights for RLYB.
Explore on BuliosFAQ
What is the fair price of RLYB?+
Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for Rallybio Corporation is $7.28. At the current market price of $9.11, RLYB trades 20.1% above its calculated fair value.
Is RLYB overvalued or undervalued?+
Rallybio Corporation is currently overvalued based on our valuation model. The stock trades at $9.11, which is 20.1% above the fair price of $7.28.
How often is RLYB's fair price updated?+
We update fair price calculations for RLYB daily after market close. The current fair price of $7.28 incorporates the latest market data and sector multiples.
What factors affect RLYB's fair price calculation?+
RLYB's fair price of $7.28 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight)., ROE of -25.2%.
Is RLYB a good buy right now?+
At $9.11, RLYB trades 20.1% above our fair value estimate of $7.28. The stock is currently overvalued. ROE stands at -25.2% (average). Fair Price Index provides valuation data — always do your own research before investing.
Does RLYB pay dividends?+
RLYB does not currently pay a dividend.